- OmniAb, Inc. (OABI, Financial) expands its Board with two strategic appointments.
- Dr. Philip J. Gotwals and Steve Crouse join the Board, increasing its size to seven members.
- Former Director Sarah Boyce steps down after six years.
OmniAb, Inc. (NASDAQ: OABI) has announced significant changes to its Board of Directors with the appointment of Dr. Philip J. Gotwals and Steve Crouse. These appointments increase the board size to seven members as they replace Sarah Boyce, who is stepping down after nearly six years of service.
Dr. Gotwals brings with him a wealth of experience in the biopharmaceutical industry, accumulating 30 years in roles such as Global Head of Business Development and Licensing at Novartis Institutes for BioMedical Research. His expertise will contribute to the Human Capital Management & Compensation and Science & Technology Committees at OmniAb.
Steve Crouse, the current Senior Vice President and General Manager of Bio-Techne's Analytical Solutions Division, adds over 20 years of life sciences expertise. He will contribute his knowledge to the Audit Committee and the Science & Technology Committee.
OmniAb's board expansion aims to enhance its governance and strategic initiatives. The company, which works with over 91 active partners in antibody technology innovation and licensing, expects to leverage the new directors' diverse expertise in advancing its growth and technological capabilities.
